On June 2, 2022 Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat and meet with investors at the in-person Jefferies Healthcare Conference (Press release, Biomea Fusion, JUN 2, 2022, View Sourcenews-releases/news-release-details/biomea-fusion-participate-jefferies-healthcare-conference" target="_blank" title="View Sourcenews-releases/news-release-details/biomea-fusion-participate-jefferies-healthcare-conference" rel="nofollow">View Source [SID1234615485]). The fireside chat will take place on Wednesday, June 8th at 2:30pm Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed at View Source and will be available for 90 days following the presentation.